Skip to main content
Justin Long, MD, Neurology, Saint Louis, MO, Barnes-Jewish Hospital

JustinMatthewLongMDPhD

Neurology Saint Louis, MO

Neurodegenerative, Dementia & Geriatrics

Assistant Professor at Washington University

Dr. Long is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Long's full profile

Already have an account?

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Dementia, 2018 - 2020
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2014 - 2018
  • Indiana University School of Medicine
    Indiana University School of MedicineClass of 2014
  • Indiana University
    Indiana UniversityPhD, Medical Neuroscience, 2007 - 2013
  • Indiana University
    Indiana UniversityBS, Biology, Highest Academic Distinction, General Honor Notation, 2001 - 2004

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2020 - 2026
  • MO State Medical License
    MO State Medical License 2017 - 2025
  • American Board of Psychiatry and Neurology Neurology

Publications & Presentations

PubMed

Journal Articles

  • Novel Upregulation of Amyloid-Β Precursor Protein (APP) by microRNA-346 via Targeting of APP mRNA 5′-Untranslated Region: Implications in Alzheimer’s Disease  
    Justin Long, MD, Nature

Press Mentions

  • COVID-19 Closes Labs, Slows Data Collection—The Impact on the Neurology Research Pipeline
    COVID-19 Closes Labs, Slows Data Collection—The Impact on the Neurology Research PipelineJuly 11th, 2020
  • Aducanumab About-Face: Experts Weigh In
    Aducanumab About-Face: Experts Weigh InJuly 11th, 2020
  • A Discontinued Alzheimer’s Trial Comes Alive Again. Will Biogen’s Aducanumab Survive the FDA Review?
    A Discontinued Alzheimer’s Trial Comes Alive Again. Will Biogen’s Aducanumab Survive the FDA Review?July 11th, 2020

Hospital Affiliations